Literature DB >> 24372073

Interferon-γ/CCR5 expression in invariant natural killer T cells and CCL5 expression in capillary veins of dermal papillae correlate with development of psoriasis vulgaris.

F Kono1, T Honda, W Aini, T Manabe, H Haga, T Tsuruyama.   

Abstract

BACKGROUND: There have been extensive studies regarding which types of T lymphocytes are involved in psoriasis vulgaris (PV). However, it has remained unclear which types of T lymphocytes might directly contribute to psoriasiform epidermal and vascular hyperplasia.
OBJECTIVES: To understand the role of T-cell receptor (TCR)Vα24+ invariant natural killer (iNK)T cells in the development of PV.
METHODS: Seventeen patients were enrolled in this study. Using biopsy samples of PV plaques, TCRVα24(+) iNKT cells were investigated regarding their cytokine production to understand their roles in development of disease.
RESULTS: The number of interferon (IFN)-γ+ iNKT cells correlated with the length of the psoriasiform hyperplasia rete ridge and the Psoriasis Area and Severity Index. IFN-γ+ iNKT cells in psoriatic skin exhibited higher C-C chemokine receptor (CCR)5 expression, and the amount of C-C chemokine ligand (CCL)5, a ligand for CCR5, was increased in capillary veins of psoriasis plaques. CCR5+ iNKT-cell numbers significantly correlated with the number of capillary vein endothelial cells expressing CCL5 in PV. Furthermore, the number of CCL5+ capillary veins correlated with the maximum rete ridge length.
CONCLUSIONS: IFN-γ/CCR5 expression in iNKT cells and CCL5 expression in vessels of dermal papillae correlate with the development of psoriasiform hyperplasia and microabscess. We propose that these iNKT cells may become useful targets for development of novel therapeutic approaches to PV.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24372073     DOI: 10.1111/bjd.12812

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  Psoriatic arthritis under the influence of IFNγ.

Authors:  Hui Dai; Iannis E Adamopoulos
Journal:  Clin Immunol       Date:  2020-06-20       Impact factor: 3.969

2.  Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response.

Authors:  Zeyu Chen; Yifan Hu; Yu Gong; Xilin Zhang; Lian Cui; Rongfen Chen; Yingyuan Yu; Qian Yu; Youdong Chen; Hongyue Diao; Jia Chen; Yuanyuan Wang; Yuling Shi
Journal:  Immunology       Date:  2020-05-25       Impact factor: 7.397

3.  Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs.

Authors:  Yin-Ku Lin; Sien-Hung Yang; Chin-Chuan Chen; Hsiao-Ching Kao; Jia-You Fang
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

4.  The association of genetic variants in chemokine genes with the risk of psoriasis vulgaris in Chinese population: A case-control study.

Authors:  Jin Zhang; Qiuhe Song; Kun Zhu; Jun Lu; Xiaogang Xiong; Fei Hao
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

5.  Evaluation of HCP5 and Chemokine C Receptor type 5 Gene Polymorphisms in Indian Psoriatic Patients.

Authors:  Deepa Rajesh; Sudeep Nagraj; K S Praveen Kumar; A V Moideen Kutty; Sharath Balakrishna
Journal:  Indian J Dermatol       Date:  2019 May-Jun       Impact factor: 1.494

6.  Age-related changes in the vasculature of the dermis of the upper lip vermilion.

Authors:  Takamasa Gomi; Toru Imamura
Journal:  Aging (Albany NY)       Date:  2019-06-06       Impact factor: 5.682

Review 7.  Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies.

Authors:  Jiangmei Xu; Hao Chen; Haisheng Qian; Fei Wang; Yunsheng Xu
Journal:  J Nanobiotechnology       Date:  2022-10-14       Impact factor: 9.429

Review 8.  T Cells in Autoimmunity-Associated Cardiovascular Diseases.

Authors:  Daniella Muallem Schwartz; Aarohan M Burma; Moses M Kitakule; Yiming Luo; Nehal N Mehta
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.